Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Abstract Text:

Tatiana Bogdanovich,Catherine Clark,Klaudia Kosowska-Shick,Bonifacio Dewasse,Pamela McGhee,Peter C Appelbaum,Tatiana Bogdanovich,Catherine Clark,Klaudia Kosowska-Shick,Bonifacio Dewasse,Pamela McGhee,Peter C Appelbaum,

Among 203 strains of Staphylococcus aureus, the MICs of CG400549 were 0.06 to 1.0 microg/ml, with MIC(50) and MIC(90) values of 0.25 microg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 microg/ml). The daptomycin MICs were 0.25 to 2.0 microg/ml for methicillin-susceptible and 0.25 to 4.0 microg/ml against methicillin-resistant strains (including vancomycin-intermediate strains). Single-passage selection testing showed low resistance frequencies with CG400549, but multistep analysis showed that CG400549 yielded resistant mutants after 14 to 17 days in all strains tested.

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Publishing Authors By Initials

T Bogdanovich,C Clark,K Kosowska-Shick,B Dewasse,P McGhee,PC Appelbaum,T Bogdanovich,C Clark,K Kosowska-Shick,B Dewasse,P McGhee,PC Appelbaum,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Antimicrobial agents and chemotherapy

VOLUME: 51

Page Numbers: 4191-5

Journal Abbreviation: Antimicrob. Agents Chemother.

ISSN: 0066-4804

DAY: 17

MONTH: 09

YEAR: 2007

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 315061

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.

AFFILIATION: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Antimicrob Agents Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents Related Publications

• A direct comparison of research decision-making capacity: Schizophrenia/schizoaffective, medically ill, and non-ill subjects.
• Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
• Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
• Agnogenic myeloid metaplasia: a case report.
• Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
• Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
• Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
• Coherent Spin Transport through a 350 Micron Thick Silicon Wafer.
• Commentary: the use of restraint and seclusion in correctional mental health.
• Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis.
• Development of autonomy: role of walking onset and its timing.
• Disclosure of information to potential subjects on research recruitment web sites.
• Ethics and forensic psychiatry: translating principles into practice.
• Genetic characterization of erythromycin- and methicillin-resistant community-acquired Staphylococcus aureus isolated from children in Texas.
• Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow.
• Hormone receptors in breast cancer.
• Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.
• In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci.
• In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae.
• Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).
• Law & psychiatry: Death row delusions: when is a prisoner competent to be executed?
• Law & psychiatry: privilege in the federal courts: should there be a "dangerous patient exception"?
• Law & psychiatry: sex offenders in the community: are current approaches counterproductive?
• Molecular characterization of multidrug-resistant Streptococcus pneumoniae isolates in Korea. The Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group.
• Patients' competence to consent to treatment.
• Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500).
• Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
• Retrolental fibroplasia; a disease of the eyes in premature infant; with report of a case.
• Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
• The voluntary patient--a psychiatrist's perspective.